Shares of Soleno were halted ahead of the company announcement of FDA approval of VYKATTM XR to treat hyperphagia.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics announces FDA approval of VYKATTM XR to treat hyperphagia
- Soleno Therapeutics trading halted, news pending
- Soleno Therapeutics resumed with a Buy at Stifel
- Optimistic Buy Rating for Soleno Therapeutics Amid Anticipated FDA Approval and Strong Financial Position
- Soleno Therapeutics Reports 2024 Financial Results and Strategic Progress